Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEANOX: LBM-normalized Oxaliplatin in Stage III Colon Cancer
NCT03255434Phase 2Active, not recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Nov 2017
- Primary completion
- Jul 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in colon cancer, sponsored by Institut du Cancer de Montpellier. Started Nov 2017; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03255434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255434.